By Dr Charlotte Rose Lemech

Book Chapters

Lemech CR; Kristeleit R; Arkenau HT, 2011, 'Novel Oncology Drug Development Strategies in the Era of Personalised Medicine', in Kapetanovic IM (ed.), Drug Discovery and Development - Present and Future

Journal articles

Zhou C; Wang B; Teng C; Yang H; Piha-Paul SA; Richardson G; Malalasekera A; Sun Y; Wang W; Liu J; Shi Y; Zhan X; Lemech C, 2025, 'A phase Ia study of a novel anti-HER2 antibody–drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors', Journal of Translational Medicine, 23, http://dx.doi.org/10.1186/s12967-024-05985-z

Thoms JAI; Yan F; Hampton HR; Davidson S; Joshi S; Saw J; Sarowar CH; Lim XY; Nunez AC; Kakadia PM; Bhuyan GS; Zou X; Nguyen M; Ghodousi ES; Koch FC; Vafaee F; Thompson IR; Karimi MM; Pickford R; Raftery MJ; Hough S; Buckland G; Bailey M; Ghodke Y; Absar N; Vaughan L; Pasalic L; Fong CY; Kenealy M; Hiwase DK; Stoddart RI; Mohammed S; Lee L; Passam FH; Larsen SR; Spring KJ; Skarratt KK; Rebeiro P; Presgrave P; Stevenson WS; Ling S; Tiley C; Fuller SJ; Roncolato F; Enjeti AK; Hoenemann D; Lemech C; Jolly CJ; Bohlander SK; Curtis DJ; Wong JWH; Unnikrishnan A; Hertzberg M; Olivier J; Polizzotto MN; Pimanda JE, 2025, 'Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs', Nature Communications, 16, http://dx.doi.org/10.1038/s41467-025-59796-x

Nindra U; Tang J; Hong JH; Descallar J; Hong M; Killen A; Dubey P; Attaullah J; Scott G; Cooper A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng W; Lemech C; Chua W, 2025, 'Prospective assessment of health-related quality of life in early phase oncology clinical trials: PEARLER', Jnci Cancer Spectrum, 9, http://dx.doi.org/10.1093/jncics/pkaf108

Lemech C; Humphries T; Biachi de Castria T; Cercek A; Overman M; Kummar S; Baldini C; Tabernero J; Hansen A; Nagrial A; Roberts K; Joshi R; Ahern E; Orr D; Al Hallak N; Van Tine BA; Waller D; Nabhan S; Drew A; Ballas M, 2025, 'Abstract B003: Orally administered MOMA-341 as monotherapy or combination therapy in participants with advanced or metastatic solid tumors: Phase 1 study design', Molecular Cancer Therapeutics, 24, pp. B003 - B003, http://dx.doi.org/10.1158/1535-7163.targ-25-b003

Kang E; Kim D; Hwang S; Lemech C; Wharton J; Lee Y; Yoo HW; Lee BH, 2025, 'A Randomized, Double-Blind, 2-Treatment, 2-Period, Crossover Phase 1 Study to Compare the Pharmacokinetics, Safety and Tolerability of 60 IU/Kg of Abcertin and Cerezyme in Healthy Volunteers Following a Single Intravenous Administration', Molecular Genetics and Genomic Medicine, 13, http://dx.doi.org/10.1002/mgg3.70111

Lemech CR; Cosman R; Humphries TG; Kichenadasse G; Richardson GE; Nagrial A; Teng C; Liu J; Joshua AM; Cohen H; Mo J; Harvey K; Zhang H; Ling Z; King N; Barnett M; Cioffi M; Maurer MA; Getts D; Swarbrick A, 2025, 'First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors.', JOURNAL OF CLINICAL ONCOLOGY, 43, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.2591

Lemech CR; Sun Y; Nagrial A; Wu X; Morris MF; Ning F; Yang J; Pan Y; Cai J; Lu P; Zhang T; Qiu F; Hu C; Zhang M; Liu Z; Han G; Nie J; Teng C; Zhou H; Day D, 2025, 'IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with HER2-positive breast cancer (BC) and other solid tumors: Updates from a phase 1 study.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. 1029 - 1029, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.1029

Atkinson VG; Brenner W; Brown JT; Cabezón-Gutiérrez L; Gajate P; Kim ST; Lee J; Lemech C; Margolin KA; Moreno I; Moreno V; Oh D-Y; Oliva IG; Park JJ; Shue H; Twardowski P; Winer I; Chisamore MJ; Prawira A; Merchant F; Coello M; To MD; Merchant R; Yavari A; Ascierto PA, 2025, 'Abstract CT047: Interim results from the phase 1/2 ABILITY-1 study of a long-acting ‘beta-enhanced not-alpha’ IL-2 superkine in patients with advanced solid tumors', Cancer Research, 85, pp. CT047 - CT047, http://dx.doi.org/10.1158/1538-7445.am2025-ct047

Tran B; Frentzas S; Lemech CR; Millward M; Day D; Desai J; Latifi A; Wabnitz P; Kearney P; Galkin AV, 2025, 'Abstract 5850: AXA-042, a systemically administered TLR2/6 agonist, demonstrates innate immune engagement and Th1 polarization in patients with advanced solid tumors', Cancer Research, 85, pp. 5850 - 5850, http://dx.doi.org/10.1158/1538-7445.am2025-5850

Nindra U; Tang J; Hong JH; Hong M; Teng C; Wei J; Killen A; Cooper A; Wilkinson K; Ng W; Lemech C; Chua W; Pal A, 2025, 'Evaluating patient diversity in early phase clinical trials in Australia through a prospective multicenter nonrandomized cohort study', Jnci Cancer Spectrum, 9, http://dx.doi.org/10.1093/jncics/pkaf035

Song Y; Xie L; Zhang Y; Wu H; Pratyush G; Huang H; Cen H; Guo Y; Fan L; Li Y; Li M; Sun X; Liang X; Lemech C; Wang J; Zhu X; Li F; Dai H; Shi Q; Yang JJ, 2025, '1316eTiP A phase Ib trial of CS5001 (ROR1-ADC) as a single agent and in combination with systemic therapies in patients with advanced solid tumours and lymphomas', Annals of Oncology, 36, pp. S822 - S823, http://dx.doi.org/10.1016/j.annonc.2025.08.1947

Lemech C; Coward J; Gao B; Park JJW; Zhou C; Moore M; Frentzas S; Gan HK; Wang J; Wang Q; Fang T; Dai H; Yue Z; La Y; Shi Q; Yang JJ, 2025, '1545P CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors: An open-label, multicenter, phase I first-in-human study', Annals of Oncology, 36, pp. S923 - S923, http://dx.doi.org/10.1016/j.annonc.2025.08.2176

Liu JJ; Farrow M; Hsing S; Cosman R; Lemech C; Teng C; Pal A; Nindra U; Parsonson A; Park JJW; Underhill CR; Hui MN; Nagrial A; Jain SS; Joshua AM, 2025, '991P PANNA-COTA (Practical assessment of NECTA network assistance in cancer outpatient trials access): A prospective investigator-led trial using ctDNA to inform early phase trial matching', Annals of Oncology, 36, pp. S649 - S649, http://dx.doi.org/10.1016/j.annonc.2025.08.1560

Lemech CR; Joubert WL; Parsonson AO; Xu R-H; Shinde R; Bhave P; Xue J; Huang Y; Meng X; Liu S-H, 2025, 'A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors.', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.tps3161

Nindra U; Tang J; Hong JH; Descallar J; Hong M; Killen AJ; Cooper AJ; Wilkinson KJ; Pal A; Teng C; Roohullah A; Wei J; Ng WL; Lemech CR; Chua W, 2025, 'Financial, social and time toxicity in early-phase cancer clinical trials: The PEARLER study.', Journal of Clinical Oncology, 43, pp. 11119 - 11119, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.11119

Nindra U; Hong JH; Tang J; Descallar J; Hong M; Killen AJ; Cooper AJ; Wilkinson KJ; Pal A; Teng C; Roohullah A; Wei J; Ng WL; Lemech CR; Chua W, 2025, 'Prospective assessment of health-related quality of life in early phase clinical trials.', Journal of Clinical Oncology, 43, pp. 11118 - 11118, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.11118

Song Y; Zhang J; Zhou K; Zhang L; Barve M; Lemech C; Li W; Cherng H-JJ; Huang H; Xie L; Zuniga R; Zhou C; Shen L; Yang S; Bishnoi S; Zhang Y; Wang J; Zhu X; Li F; Yang J, 2024, 'Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC', Blood, 144, pp. 1739 - 1739, http://dx.doi.org/10.1182/blood-2024-192979

Hayes AG; Jonker B; Teng C; Lemech C; Killen AJ; Sim HW; McCormack AI, 2024, 'Approach to the Patient: New Era Emerges for Craniopharyngioma Management', Journal of Clinical Endocrinology and Metabolism, 109, pp. 2986 - 2996, http://dx.doi.org/10.1210/clinem/dgae503

Lemech CR; Zuniga R; Barve MA; Song Y; Zhang J; Zhou K; Zhang L; Shen L; Bishnoi S; Cherng H-JJ; Zhou C; Li W; Wang J; Zhu X; Zhu D; Li F; Shen Z; Yang J, 2024, 'A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.', Journal of Clinical Oncology, 42, pp. 3023 - 3023, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3023

Armstrong AJ; Geva R; Chung HC; Lemech C; Miller WH; Hansen AR; Lee JS; Tsai F; Solomon BJ; Kim TM; Rolfo C; Giranda V; Ren Y; Liu F; Kandala B; Freshwater T; Wang JS, 2024, 'Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial(Investigational New Drugs, (2024), 42, (145-159), 10.1007/s10637-023-01410-2)', Investigational New Drugs, 42, pp. 340 - 341, http://dx.doi.org/10.1007/s10637-024-01444-0

Wahlroos S; Teng C; Tran B; Voskoboynik M; Gan HK; Spencer A; Kudva A; Song M; Lynch K; Yu Z; Desai J; Lemech CR, 2024, 'Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors.', Journal of Clinical Oncology, 42, pp. e15114 - e15114, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e15114

Frentzas S; Mislang ARA; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG, 2024, 'Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors', Journal for Immunotherapy of Cancer, 12, http://dx.doi.org/10.1136/jitc-2023-008037

Dorff T; Horvath LG; Autio K; Bernard-Tessier A; Rettig MB; Machiels JP; Bilen MA; Lolkema MP; Adra N; Rottey S; Greil R; Matsubara N; Tan DSW; Wong A; Uemura H; Lemech C; Meran J; Yu Y; Minocha M; McComb M; Penny HL; Gupta V; Hu X; Jurida G; Kouros-Mehr H; Janat-Amsbury MM; Eggert T; Tran B, 2024, 'A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer', Clinical Cancer Research, 30, pp. 1488 - 1500, http://dx.doi.org/10.1158/1078-0432.CCR-23-2978

Cheng Y; Lisberg A; Lemech C; Abed A; Chaudhry A; Schmidt A; Lu X; Zhu Z; Gu W; Qiu Y; Shi R; Zhang B, 2024, 'Abstract CT165: A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumors', Cancer Research, 84, pp. CT165 - CT165, http://dx.doi.org/10.1158/1538-7445.am2024-ct165

Atkinson VG; Antras JF; Bedard P; Brenner W; Brown J; Lemech CR; Lloyd P; Margolin K; Mathew M; Park JJ; Thomas S; Twardowski P; Gardner H; Prawira A; Coello M; Ebrahimimizadeh W; To MD; Merchant R; Karanam SM; Yavari A; Siu LL; Tawbi HA; Ascierto PA, 2024, 'Abstract CT259: Results from monotherapy dose escalation of MDNA11, a long-acting IL-2 superkine, in a phase 1/2 trial show evidence of single-agent activity in advanced solid tumors', Cancer Research, 84, pp. CT259 - CT259, http://dx.doi.org/10.1158/1538-7445.am2024-ct259

Armstrong AJ; Geva R; Chung HC; Lemech C; Miller WH; Hansen AR; Lee JS; Tsai F; Solomon BJ; Kim TM; Rolfo C; Giranda V; Ren Y; Liu F; Kandala B; Freshwater T; Wang JS, 2024, 'CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial', Investigational New Drugs, 42, pp. 145 - 159, http://dx.doi.org/10.1007/s10637-023-01410-2

Tran B; Voskoboynik M; Bendell J; Gutierrez M; Lemech C; Day D; Frentzas S; Garrido-Laguna I; Standifer N; Wang F; Ferte C; Wang Y; Das M; Carneiro BA, 2024, 'A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors', Immunotherapy, 16, pp. 759 - 774, http://dx.doi.org/10.1080/1750743X.2024.2359359

Thoms J; Hampton H; Yan F; Davidson S; Joshi S; Sarowar C; Lim XY; Nunez A; Kakadia P; Saw J; Bhuyan GS; Zou X; Ghodousi E; Jolly C; Koch F; Vafaee F; Pickford R; Raftery M; Hough S; Buckland G; Bailey M; Ghodke Y; Absar N; Vaughan L; Pasalic L; Fong C; Kenealy M; Hiwase D; Stoddart R; Mohammed S; Lee L; Passam F; Spring K; Skarratt K; Rebeiro P; Larsen S; Presgrave P; Stevenson W; Ling S; Tiley C; Fuller S; Roncolato F; Enjeti A; Hoenemann D; Lemech C; Curtis D; Bohlander S; Olivier J; Hertzberg M; Unnikrishnan A; Polizotto M; Pimanda J, 2024, '3178 – LONGITUDINAL DRUG INCORPORATION, CLONAL COMPOSITION, AND DNA METHYLATION DYNAMICS IN MDS/CMML PATIENTS TREATED WITH AZA', Experimental Hematology, 137, pp. 104498 - 104498, http://dx.doi.org/10.1016/j.exphem.2024.104498

Lemech C; Sun Y; Nagrial A; Wu X; Morris M; Ning F; Yang J; Pan Y; Cai J; Lu P; Zhang T; Qiu F; Hu C; Zhang M; Liu Z; Han G; Nie J; Teng C; Zhou H; Day D, 2024, '345MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study', Annals of Oncology, 35, pp. S360 - S360, http://dx.doi.org/10.1016/j.annonc.2024.08.293

Gong J; Lemech C; Day D; Shan J; Morris M; Nagrial A; Chen M; Huang X; Zong H; Wang N; Yang Y; Yi T; Li W; Zhuang Z; Li Z; Liu Z; Luo Y; Zhang Y; Zhou H; Shen L, 2024, '576P Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study', Annals of Oncology, 35, pp. S467 - S468, http://dx.doi.org/10.1016/j.annonc.2024.08.645

Cheng Y; Wu L; Parsonson A; Amin H; Shi J; Lemech C; Sun Y; Schmidt A; Lv D; Li M; Zheng T; Chaudhry A; Gandhi C; Wang Q; Motino DAM; Abed A; Tibes R; Lu X; Gu V; Lisberg AE, 2024, '57O A phase I/II multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors', Annals of Oncology, 35, pp. S1426 - S1426, http://dx.doi.org/10.1016/j.annonc.2024.10.078

Lemech C; Luke JJ; Falchook GS; Mckean M; Kichenadasse G; Teng C; Vandross AL; Salkeni MA; Atkinson VG; Liu JJ; Kennedy AM; Clark J; Ryan M; Schmidt-Kittler O; Steinhubel D; Wages D; Komarnitsky P; Puzanov I, 2024, 'A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations', ANNALS OF ONCOLOGY, 35, pp. S528 - S529, http://dx.doi.org/10.1016/j.annonc.2024.08.744

Mercuri FA; White S; McQuilten HA; Lemech C; Mynhardt S; Hari R; Zhang P; Kruger N; McLachlan G; Miller BE; West NP; Tal-Singer R; Demaison C, 2024, 'Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology.', ERJ Open Res, 10, http://dx.doi.org/10.1183/23120541.00199-2024

Lemech C; Kichenadasse G; Teng C; Nagrial A; Richardson G; Humphries TG; Killen AJ; Joshua A; Liu JJ; Churchill M; Barnett M; Cioffi M; Cosman R, 2024, 'MYE Symphony: A first-in-human study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the in vivo mRNA CAR therapy, MT-302, targeting TROP2 in adults with advanced epithelial tumors', ANNALS OF ONCOLOGY, 35, pp. S528 - S528, http://dx.doi.org/10.1016/j.annonc.2024.08.742

Lee S-H; Han J-Y; Lee KH; Lee G-W; Lemech C; Millward M; Roohullah A; Le X; Park K; Choi JY; Kim NY; Im S; Rajasekaran N; Park KE; Lee S; Moon H; Hwang S; Shin Y; Lee DH, 2023, 'Abstract B042: Efficacy and safety outcomes of ABN401 in NSCLC patients with MET Exon 14 Skipping: A clinically relevant subgroup analysis', Molecular Cancer Therapeutics, 22, pp. B042 - B042, http://dx.doi.org/10.1158/1535-7163.targ-23-b042

Day D; Park JJ; Coward J; Markman B; Lemech C; Kuo JC; Prawira A; Brown MP; Bishnoi S; Kotasek D; Strother RM; Cosman R; Su R; Ma Y; Yue Z; Hu HH; Wu R; Li P; Tse AN, 2023, 'A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer', British Journal of Cancer, 129, pp. 1608 - 1618, http://dx.doi.org/10.1038/s41416-023-02431-7

Wynne CJ; Cole A; Lemech C; Wang G; Zhang Y; Chen B; Wang M; Li B; Xia M; Sinclair R, 2023, 'Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study', Dermatology and Therapy, 13, pp. 2357 - 2373, http://dx.doi.org/10.1007/s13555-023-01010-1

Fries L; Formica N; Mallory RM; Zhou H; Plested JS; Kalkeri R; Moldovan I; Patel N; Albert G; Robinson M; Cho I; Chau G; Dubovsky F; Glenn GM; Adams M; Arya M; Athan E; Berger I; Bradley P; Glover R; Griffin P; Kim J; Kitchener S; Klein T; Leah A; Lemech C; Lickliter J; Manning MB; Napier-Flood F; Nugent P; Thackwray S; Turner M, 2023, 'Strong CD4+T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination', Journal of Infectious Diseases, 228, pp. 734 - 741, http://dx.doi.org/10.1093/infdis/jiad163

Kalac M; Hertzberg M; Cheah C; Ribrag V; Abrisquet Acosta P; Opat S; Bachy E; Ysebaert L; Qiu L; Yi S; Nishimura N; Lemech C; Bussolari J; Deng C; Lu T; Xiu L; Van Hemelryck S; Philippar U; Guo Y; Soete V; Soriano I; Fourneau N; Gerecitano J; Morschhauser F, 2023, 'P624: PHASE 1 STUDY OF JNJ-67856633, A FIRST-IN-HUMAN HIGHLY SELECTIVE MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)', HemaSphere, 7, pp. e60782b9 - e60782b9, http://dx.doi.org/10.1097/01.hs9.0000969400.60782.b9

Lee DH; Han J-Y; Lemech CR; Millward M; Roohullah A; Choi JY; Park KE; Kim NY; Im S; Rajasekaran N; Lee S; Moon H; Hwang S; Shin Y; Lee S-H, 2023, 'ABN401 in patients with NSCLC with MET exon 14 (METex14) skipping: Result from the pilot expansion study.', JOURNAL OF CLINICAL ONCOLOGY, 41, pp. e21148 - e21148, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.e21148

Lemech CR; Argent C; Scribner CL; Sharabi A; Daniels R; Appleman JR, 2023, 'Abstract CT180: Activation of innate and adaptive immune response with a clinical stage TLR7 agonist prodrug PRTX007', Cancer Research, 83, pp. CT180 - CT180, http://dx.doi.org/10.1158/1538-7445.am2023-ct180

Fu S; Falchook GS; Barve M; McKean M; Tan TJ; Lemech C; Chee CE; Marina N; Abbadessa G; Meng R; Rotolo F; Wang H; Deng J; Wang W; Wang R; Meniawy T, 2023, 'Abstract 2155: Joint modeling of safety and peripheral mode-of-action (MoA) biomarkers to support RP2D identification in Phase 1 study of SAR444245 (SAR’245) as monotherapy (mono) or combined with pembrolizumab (pembro) in patients with advanced solid tumors', Cancer Research, 83, pp. 2155 - 2155, http://dx.doi.org/10.1158/1538-7445.am2023-2155

Lemech CR; Kichenadasse G; Marschner JP; Alevizopoulos K; Otterlei M; Millward M, 2023, 'ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study', Oncogene, 42, pp. 541 - 544, http://dx.doi.org/10.1038/s41388-022-02582-6

Lemech C; Dredge K; Bampton D; Hammond E; Clouston A; Waterhouse NJ; Stanley AC; Leveque-El Mouttie L; Chojnowski GM; Haydon A; Pavlakis N; Burge M; Brown MP; Goldstein D, 2023, 'Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors', Journal for Immunotherapy of Cancer, 11, http://dx.doi.org/10.1136/jitc-2022-006136

Strickler JH; Satake H; George TJ; Yaeger R; Hollebecque A; Garrido-Laguna I; Schuler M; Burns TF; Coveler AL; Falchook GS; Vincent M; Sunakawa Y; Dahan L; Bajor D; Rha SY; Lemech C; Juric D; Rehn M; Ngarmchamnanrith G; Jafarinasabian P; Tran Q; Hong DS, 2023, 'Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer', New England Journal of Medicine, 388, pp. 33 - 43, http://dx.doi.org/10.1056/NEJMoa2208470

Weickhardt AJ; Frentzas S; Lemech C; Srimani J; Yin J; Trepicchio WL; Gorgun C; Kichenadasse G, 2023, 'A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR 3 CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors', ANNALS OF ONCOLOGY, 34, pp. S492 - S492, http://dx.doi.org/10.1016/j.annonc.2023.09.1897

Tran B; Millward M; Lemech C; Frentzas S; Day D; Latifi A; Desai J; Wabnitz P; Kearney P; Galkin A, 2023, 'AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors', ANNALS OF ONCOLOGY, 34, pp. S635 - S635, http://dx.doi.org/10.1016/j.annonc.2023.09.2186

Vickers D; Port K; Li J; Eather S; Cranney G; Lemech C; Singarayar S, 2023, 'Novel Use of Micra AV Pacemaker for Immune Checkpoint Inhibitor-associated Myocarditis, Life-sustaining Ventricular Tachycardia and Atrioventricular Dissociation', Heart, Lung and Circulation, 32, pp. S343 - S343, http://dx.doi.org/10.1016/j.hlc.2023.06.782

Hertzberg M; Kalac M; Cheah CY; Ribrag V; Abrisqueta P; Opat S; Bachy E; Ysebaert L; Qiu L; Yi S; Nishimura N; Lemech C; Bussolari J; Deng C; Lu T; Xiu L; Hemelryck SV; Philippar U; Guo Y; Soete V; Paradinas IS; Fourneau N; Gerecitano J; Morschhauser F, 2023, 'PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)', Hematological Oncology, 41, pp. 131 - 132, http://dx.doi.org/10.1002/hon.3163_88

Back to profile page